|
Oct 9
|
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
|
|
Oct 7
|
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
|
|
Sep 23
|
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
|
Sep 6
|
CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
|
|
Sep 5
|
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
|
|
Sep 4
|
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
|
|
Sep 4
|
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes
|
|
Sep 4
|
High-dose Spinraza meets study goal; Top Dyne executives exit
|
|
Sep 3
|
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
|
|
Sep 3
|
Dyne Therapeutics Announces Key Leadership Appointments
|
|
Sep 3
|
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
|
|
Aug 12
|
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
|
Jul 29
|
Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
|
|
Jun 24
|
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
|
|
May 19
|
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
|
|
May 4
|
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
|
|
May 4
|
Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections
|
|
May 2
|
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Mar 27
|
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
|
|
Mar 27
|
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
|